Morgan Stanley Asia Singapore has sold 17.32 lakh shares of Aurobindo Pharma through the open market route. The shares were sold on an average price of Rs 669.92 valuing the transaction at Rs 116.06 crore. On the other hand, Abu Dhabi Investment Authority has bought 14.75 shares in the company for an average price of Rs 670.51, through open market route valuing the transaction at Rs 98.95 crore.
Aurobindo Pharma manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up.
